Lipoxin A4

CAS: 89663-86-5

Ref. 3D-PDA66386

Información del producto

• Nombre: Lipoxin A4
• Sinónimos: (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-Trihydroxy-7,9,11,13-eicosatetraenoic acid, (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid, 5S,6R,15S-Trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid, 7,9,11,13-Eicosatetraenoic acid, 5,6,15-trihydroxy-, (5S,6R,7E,9E,11Z,13E,15S)-, 7,9,11,13-Eicosatetraenoic acid, 5,6,15-trihydroxy-, [5S-(5R*,6S*,7E,9E,11Z,13E,15R*)]-, LXA₄, Lipoxin A, Lipoxin A₄

Descripción

Lipoxin A4 is an inhibitor that has been shown to have potent anticancer activity. It has been found to inhibit the growth of tumor cells in Chinese hamster ovary cells and human cancer cell lines. Lipoxin A4 is a protein kinase inhibitor that targets several kinases, including Akt, ERK1/2, and p38 MAPK. This drug has also been found to induce apoptosis in cancer cells by activating caspase-3 and other apoptotic pathways. In addition to its anticancer properties, Lipoxin A4 has also been investigated as an anti-inflammatory agent and has shown promising results in animal models of inflammation. Lipoxin A4 analogs have been developed for use as potential therapeutic agents, including dabigatran, a direct thrombin inhibitor used for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 352.5 g/mol
• Fórmula: C₂₀H₃₂O₅
• Pureza: Min. 95%